Gemini Therapeutics Announces Appointment of Georges Gemayel, Ph.D. as Chair of Board of Directors
May 03 2021 - 7:00AM
Business Wire
Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage
precision medicine company developing innovative treatments for
genetically defined age-related macular degeneration (AMD) and
linked ocular disorders, today announced the appointment of Georges
Gemayel, Ph. D., as the Chair of the Company’s Board of
Directors.
“I am pleased to welcome Georges to Gemini’s Board of Directors
during this important time in our Company’s maturation, as we
advance our lead program into the next stages of clinical
development,” said Jason Meyenburg, Chief Executive Officer of
Gemini Therapeutics. “Georges’ broad management experience and
proven track record of commercial and product development success
will be invaluable as we continue to advance our pipeline of novel
precision medicines.”
Dr. Gemayel has over 30 years of experience in the
pharmaceutical industry, including management and executive
positions in the U.S., Europe and the Middle East. Dr. Gemayel
currently serves on the board of directors of Supernus
Pharmaceuticals, Inc., and is the chair of the boards of Dynacure,
OxThera AB, Enterome SA, and Orphazyme A/S. Previously, Dr. Gemayel
served as Executive Chair of FoldRx Pharmaceuticals and of Syndexa
Pharmaceuticals, as Chair of Dimension Therapeutics and
Epitherapeutics and as Director of Prosensa, Raptor
Pharmaceuticals, NPS Pharma, Momenta Pharmaceuticals and
Adolor.
"Gemini has a very exciting approach to treat dry AMD that could
bring to the market a best-in-class product said Dr. Gemayel. "I
look forward to working with management and with my fellow
directors to advance Gemini and the Company’s innovative pipeline
of precision medicine therapeutic candidates.”
From 2008 to 2009, Dr. Gemayel was President and Chief Executive
Officer of Altus Pharmaceuticals Inc., a publicly traded
pharmaceutical company. From 2003 to 2008, he was Executive Vice
President at Genzyme Corporation where he was responsible for the
company's global therapeutics, transplant, renal and biosurgery
businesses. From 1998 to 2003, he held progressively senior roles
at Hoffmann La-Roche Ltd. and Roche Labs, most recently as Vice
President, National Specialty Care, responsible for its U.S.
business for dermatology, oncology, transplantation, hepatitis and
HIV. Dr. Gemayel completed his doctorate in pharmacy at St. Joseph
University in Beirut, Lebanon, and earned a Ph.D. in pharmacology
at Paris-Sud University in Paris, France.
About Gemini Therapeutics
Gemini Therapeutics is a clinical stage precision medicine
company developing novel therapeutic compounds to treat genetically
defined age-related macular degeneration (AMD). Gemini’s lead
candidate, GEM103, is a recombinant form of human complement factor
H protein (CFH) and is designed to address both complement
hyperactivity and restore retinal health in patients with AMD.
GEM103 is currently in a Phase 2a trial in dry AMD patients with a
CFH risk variant and a Phase 1/2a study in patients with
neovascular age-related macular degeneration with or at risk for
macular atrophy. The Company has generated a rich pipeline
including recombinant proteins, gene therapies, and monoclonal
antibodies and is advancing a potentiating antibody for CFH,
GEM307, into clinical development for treatment of systemic
diseases.
For more information, visit www.geminitherapeutics.com.
Gemini’s Forward-Looking Statements
Certain statements in this press release and the information
incorporated herein by reference may constitute “forward-looking
statements” for purposes of the federal securities laws. Our
forward-looking statements include, but are not limited to,
statements regarding our or our management team’s expectations,
hopes, beliefs, intentions or strategies regarding the future,
including those relating to the success, cost and timing of our
product development activities and clinical trials, including our
estimates regarding when data will be reported from ongoing
clinical trials and the timing to commence future clinical trials,
the potential attributes and benefits of our product candidates,
including GEM103, our ability to obtain and maintain regulatory
approval for our product candidates, our projected cash runway and
our ability to obtain funding for our operations when needed.
Forward-looking statements include statements relating to our
management team’s expectations, hopes, beliefs, intentions or
strategies regarding the future. In addition, any statements that
refer to projections, forecasts or other characterizations of
future events or circumstances, including any underlying
assumptions, are forward-looking statements. The words
“anticipate,” “believe,” “contemplate,” “continue,” “could,”
“estimate,” “expect,” “intends,” “may,” “might,” “plan,”
“possible,” “potential,” “predict,” “project,” “should,” “will,”
“would” and similar expressions may identify forward-looking
statements, but the absence of these words does not mean that a
statement is not forward-looking. These forward-looking statements
are based on current expectations and beliefs concerning future
developments and their potential effects. There can be no assurance
that future developments affecting us will be those that we have
anticipated. These forward-looking statements involve a number of
risks, uncertainties (some of which are beyond our control) or
other assumptions that may cause actual results or performance to
be materially different from those expressed or implied by these
forward-looking statements. These risks and uncertainties include,
but are not limited to, those factors described under the heading
“Risk Factors” in the final proxy/prospectus for our recently
completed business combination, and those that are included in any
of our future filings with the SEC. Should one or more of these
risks or uncertainties materialize, or should any of our
assumptions prove incorrect, actual results may vary in material
respects from those projected in these forward-looking statements.
Some of these risks and uncertainties may in the future be
amplified by the COVID-19 pandemic and there may be additional
risks that we consider immaterial, or which are unknown. It is not
possible to predict or identify all such risks. Our forward-looking
statements only speak as of the date they are made, and we do not
undertake any obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise, except as may be required under applicable securities
laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210503005036/en/
Investor: Argot Partners Sherri Spear 212-600-1902
gemini@argotpartners.com
Media: Argot Partners Joshua Mansbach 212-600-1902
gemini@argotpartners.com
Gemini Therapeutics (NASDAQ:GMTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Gemini Therapeutics (NASDAQ:GMTX)
Historical Stock Chart
From Sep 2023 to Sep 2024